DBV Technologies Reports March 31, 2017 Cash Position
(Thomson Reuters ONE) -
Press Release
Montrouge, France, April 28, 2017
DBV Technologies Reports March 31, 2017 Cash Position
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced its cash and cash equivalents as of March 31, 2017.
Cash and cash equivalents
DBV's cash and cash equivalents amounted to ?227.0 million as of March
31, 2017, compared to ?256.5 million as of December 31, 2016.
Number of outstanding and fully diluted shares
As of March 31, 2017, DBV's number of outstanding shares was 24,668,838 ordinary
shares and on a fully diluted basis[i], the number of shares was 27,338,071.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
--------------------------------------------------------------------------------
[i] fully diluted share capital represents all issued and outstanding shares, as
well as all potential shares which may be issued upon exercise of outstanding
employee warrants, employee performance shares and share options and nonemployee
warrants, as approved by DBV Technologies shareholders and granted by the board
of directors.
PDF version:
http://hugin.info/156437/R/2099919/795847.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 538988
Anzahl Zeichen: 3596
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 187 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Reports March 31, 2017 Cash Position"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
